CMM researchers lead IMI-funded projects with the highest publication output
The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. In the latest IMI report, published on December 17th, BTCure, a project aimed at a deeper understanding of the pathology of rheumatoid arthritis, and coordinated by CMM Group Leader Lars Klareskog, continued to be the most productive IMI-funded project in terms of publications.
Michael Sundström is the scientific director of ULTRA-DD, aimed at identification and validation of under-explored novel targets in auto-immune and inflammatory diseases, as well as one of the scientific directors of EUbOPEN, a project that aims at creating open access libraries of annotated drug targets and corresponding chemical probes. ULTRA-DD and EUbOPEN reached the 3rd and 7th best position, respectively, in this year’s IMI ranking.